Abstract
Epithelial-mesenchymal transition (EMT) is a vital process implemented in embryo development, organ fibrosis, and cancer metastasis. Several transcription factors and signaling pathways impinge on the transcriptional program of the cell, leading to the change of cell phenotype without alteration of genotype. Accumulating evidence suggests that epigenetic mechanisms play important roles in inducing EMT and orchestrating the heredity and reversibility of EMT. In this review, we discuss how DNA methylation, histone modifications, and microRNAs (miRNAs) act in a concerted manner to regulate EMT. ‘Epigenetic therapies’—inhibitors of DNA methyltransferases and histone deacetylases as well as microRNAs are emerging as promising agents for cancer intervention.
Keywords: DNMT inhibitors, EMT, epigenetic regulation, epigenetic therapy, HDAC inhibitors, metastasis, miRNAs.
Current Cancer Drug Targets
Title:Epigenetic Regulation of Epithelial to Mesenchymal Transition
Volume: 13 Issue: 9
Author(s): Peiwei Huangyang and Yongfeng Shang
Affiliation:
Keywords: DNMT inhibitors, EMT, epigenetic regulation, epigenetic therapy, HDAC inhibitors, metastasis, miRNAs.
Abstract: Epithelial-mesenchymal transition (EMT) is a vital process implemented in embryo development, organ fibrosis, and cancer metastasis. Several transcription factors and signaling pathways impinge on the transcriptional program of the cell, leading to the change of cell phenotype without alteration of genotype. Accumulating evidence suggests that epigenetic mechanisms play important roles in inducing EMT and orchestrating the heredity and reversibility of EMT. In this review, we discuss how DNA methylation, histone modifications, and microRNAs (miRNAs) act in a concerted manner to regulate EMT. ‘Epigenetic therapies’—inhibitors of DNA methyltransferases and histone deacetylases as well as microRNAs are emerging as promising agents for cancer intervention.
Export Options
About this article
Cite this article as:
Huangyang Peiwei and Shang Yongfeng, Epigenetic Regulation of Epithelial to Mesenchymal Transition, Current Cancer Drug Targets 2013; 13 (9) . https://dx.doi.org/10.2174/15680096113136660103
DOI https://dx.doi.org/10.2174/15680096113136660103 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Haptotactic Gradients for Directed Cell Migration: Stimulation and Inhibition Using Soluble Factors
Combinatorial Chemistry & High Throughput Screening Non-diabetic Glucose levels and Cancer Mortality: A Literature Review
Current Diabetes Reviews Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach
Current Gene Therapy Tumor Specific Imaging Using Tc-99m and Ga-68 Labeled Radiopharmaceuticals
Current Medical Imaging Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis
Current Molecular Pharmacology The Potential of Ellagic Acid as a Possible Antimalarial Drug Candidate
Current Bioactive Compounds The Dynamics of the Hypothalamic-Pituitary-Ovarian Axis, ReproductivePerformance and Sexuality Following Bariatric Surgery
Current Women`s Health Reviews NAD+-Linked 15-Hydroxyprostaglandin Dehydrogenase: Structure and Biological Functions
Current Pharmaceutical Design Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets Cholecystokinin Antagonists A New Way to Improve the Analgesia from Old Analgesics?
Current Pharmaceutical Design EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Inflammation, Microenvironment, and the Immune System in Cancer Progression
Current Pharmaceutical Design Nicotine Addiction and Coronary Artery Disease: Impact of Cessation Interventions
Current Pharmaceutical Design Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma
Anti-Cancer Agents in Medicinal Chemistry Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents
Current Medicinal Chemistry Liquid-Crystalline Nanodispersions Containing Monoolein for Photodynamic Therapy of Skin Diseases: A Mini-Review
Current Nanoscience Current Concepts in Reprogramming Somatic Cells to Pluripotent State
Current Stem Cell Research & Therapy Cell Sheet-Based Myocardial Tissue Engineering: New Hope for Damaged Heart Rescue
Current Pharmaceutical Design